Research Programs Discontinued
0
Drugs Discontinued
0
since passage of the Inflation Reduction Act
News Updates
Incubate’s Investment Tracker measures the impacts of the Inflation Reduction Act’s healthcare provisions on the life sciences ecosystem, with special attention to the impacts of the small molecule penalty.
Date
Disease Area
Drug Type
Announcement Type
Company Size
Search
August 31, 2026
Telomere Theraperutics SL
Orphan Drug Designation
Madrid
1-50 employees
treatment of idiopathic pulmonary fibrosis
Disease Area: Rare Diseases
August 30, 2026
AstraZeneca Pharmaceuticals LP
Orphan Drug Designation
treatment of esophageal cancer
Disease Area: Rare Diseases
August 27, 2026
Biomed Valley Discoveries Inc.
Orphan Drug Designation
Kansas City
1-50 employees
treatment of malignant glioma
Disease Area: Rare Diseases
August 27, 2026
Kalevala Therapeutics, Inc.
Orphan Drug Designation
Dover
1-50 employees
treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)
Disease Area: Rare Diseases
August 27, 2026
Mirkine Pharma, Incorporated
Orphan Drug Designation
New York
1-50 employees
treatment of pancreatic cancer
Disease Area: Rare Diseases
August 26, 2026
RayzeBio, Inc.
Orphan Drug Designation
San Diego
1-50 employees
treatment of gastroenteropancreatic neuroendocrine tumors
Disease Area: Rare Diseases
August 26, 2026
X4 Pharmaceuticals, Inc.
Orphan Drug Designation
Boston
1-50 employees
treatment of congenital neutropenia
Disease Area: Rare Diseases
August 25, 2026
Kedrion S.p.A
Orphan Drug Designation
treatment of stiff person syndrome
Disease Area: Rare Diseases
August 24, 2026
SillaJen Inc.
Orphan Drug Designation
Seoul
1-50 employees
treatment of acute myeloid leukemia
Disease Area: Rare Diseases
August 24, 2026
LILA Holding AG
Orphan Drug Designation
Kusnacht
1-50 employees
treatment of Gaucher disease
Disease Area: Rare Diseases